CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 75 enrolled
Drug / intervention
glargine +1 moredrug
Likely dose
0.3 units/kg of insulin glargine, subcutaneously, onceAI-extracted
Key inclusion· 7
  • Age 6-18 years old
  • Established history of insulin dependent diabetes
  • Presenting with hyperglycemia or vomiting
  • Venous pH < 7.24
Key exclusion· 7
  • Age < 6 years old
  • New onset diabetes (not established)
  • Received IV insulin bolus prior to arrival at emergency room
  • Venous pH > 7.24 (insufficient acidosis for DKA diagnosis)

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00179127
NCT00179127N/ACompleted

Early Use of Insulin Glargine in Diabetic Ketoacidosis

Vanderbilt University Medical Center·interventional·Posted Sep 15, 2005·Updated Jul 16, 2018

In Brief

A clinical study evaluating glargine and saline for Diabetic Ketoacidosis. Completed, enrolled 75 participants across 1 site.

Detailed Summary

The purpose of this study is to determine the effects of the addition of insulin glargine during the early phase of moderate to severe Diabetic Ketoacidosis (DKA) in children. The investigators hypothesize that the addition of insulin glargine during the early phase of management of DKA will accelerate acidosis correction, decrease the length of insulin infusion, and decrease the total intensive care unit time in children admitted to the ICU.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 15, 2005
Enrollment StartAug 1, 2004
Primary CompletionJul 1, 2009
Study CompletionSep 1, 2012
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 20.8 years ago

Interventions

glarginedrug

0.3u/kg of glargine, subcutaneously, once

salinedrug

0.3u/kg of saline, subcutaneously, once